Vimarsana
Biggest News Aggregation in the World

Page 12 - Abilify Maintena News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Abilify Maintena. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Abilify Maintena Today - Breaking & Trending Today

PsyBio Therapeutics Appoints Pharmaceutical Veteran Bob Oliver to its Board of Directors - Vimarsana News

PsyBio Therapeutics Appoints Pharmaceutical Veteran Bob Oliver to its Board of Directors

PsyBio Therapeutics Appoints Pharmaceutical Veteran Bob Oliver to its Board of Directors Mr. Oliver joins PsyBio bringing over 25 years of executive pharmaceutical experience having held various senior positions at Otsuka, Wyeth and Johnson & Johnson News provided by Share this article Share this article PsyBio" or the " Company"), a biotechnology company pioneering the next generation of targeted psychoactive medications, is pleased to announce the appointment of Mr. Bob Oliver to the Company's board of directors (the " Board"), effective immediately. The Company is developing a platform tec...

Lundbeck still feeling effects from Cipralex patent loss - Vimarsana News

Lundbeck still feeling effects from Cipralex patent loss

Lundbeck still feeling effects from Cipralex patent loss The antidepressant sales dropped another 33% in the third quarter New products launched by Lundbeck over recent years were not enough to compensate for poor performance in the third quarter, although the company made big gains in the US. Revenues fell 6% to 10.22bn Danish krone ($1.71bn) as generics continued to take their toll on former big seller antidepressant Cipralex (escitalopram), which lost another 33% of sales to reach 983m krone. The sale of a block of mature products in the US as well as a big spend on new product launches al...

Source: pmlive.com
Perception Neuroscience And Otsuka Pharmaceutical Announce Collaboration On Development Of PCN-101 (R-ketamine) In Japan For Treatment-of Depressive Disorders - Vimarsana News

Perception Neuroscience And Otsuka Pharmaceutical Announce Collaboration On Development Of PCN-101 (R-ketamine) In Japan For Treatment-of Depressive Disorders

Share this article Share this article NEW YORK and TOKYO, March 16, 2021 /PRNewswire/ -- Perception Neuroscience (Perception), an atai Life Sciences (atai) company focused on developing innovative therapies in neuropsychiatric disorders, and Otsuka Pharmaceutical Co., Ltd. (Otsuka), announce a collaboration and licensing agreement for the development and commercialization of Perception's lead molecule, PCN-101 (R-ketamine) in Japan as a potential treatment for mood disorders such as major depressive disorder (MDD) and treatment-resistant depression (TRD). Outside of Japan, Perception is devel...

Caring for a Loved One During the Covid-19 Pandemic - Vimarsana News

Caring for a Loved One During the Covid-19 Pandemic

(BPT) - Sponsored by Alkermes In the midst of a global pandemic, Ashley and Kim, a Texas-based mother-daughter duo working together to treat Kim’s schizophrenia, have seen one surprising emotion rise to the surface: pride. “She’s had some down days, but honestly I’m really proud of her. She’s handling the pandemic the best she can,” said Ashley, a caregiver for her mother Kim, who was diagnosed with schizophrenia when she was 30 years old. While experts say that mental health challenges have become more widespread during the COVID-19 pandemic, 1 Ashley has seen s...